TCGX

We are pleased to announce that TCGX led the $135 million Series B financing of Adcendo, a first-in-class Danish biotech company developing ADC programs for the treatment of cancers with high unmet needs. Cariad Chester, Managing Partner of TCGX, joined Adcendo’s Board of Directors and commented: "ADCs have transformed the clinical landscape and standard of care in the treatment of?solid tumors. Continued progress?for?hard-to-treat cancers will require?innovative approaches?and I’m confident Adcendo will be a leader in the next era of ADC drug development. With this financing, Adcendo can rapidly advance a pipeline of exciting, differentiated ADC candidates. These programs have the potential to significantly change the treatment paradigm?in multiple cancers and serve patients in need of better therapies.” Please read more about this development via: https://lnkd.in/e6VCBxDm.

TCGX recently led the $100 Million Series B Financing in Vicebio. Managing Partner at TCGX, Cariad Chester, will join the Board of Directors and shared: "At TCGX, we are dedicated to supporting the translation of cutting-edge science into transformative medicines and we are thrilled to partner with Vicebio. This is a highly experienced team with a breakthrough technology to address a critical public health need. Vicebio has a unique capability to advance vaccine products that simultaneously provide robust immune responses against multiple respiratory pathogens. We look forward to working closely with the team to bring these important vaccines to market." Joining TCGX were premier biotech funds representing Goldman Sachs, Avoro Capital, venBio, and founding investor Medicxi. We look forward to the success of Vicebio. Learn more about the Series B financing and the Phase I clinical trial at Vicebio in the full press release: https://lnkd.in/e_uiAqbz

We are excited to announce that TCGX joined the Series B financing of Beacon Therapeutics (https://www.beacontx.com/). Beacon is a pioneering gene therapy company advancing best-in-class programs for X-linked retinitis pigmentosa and dry age-related macular degeneration. This investment funds Beacon's registrational Phase 3 clinical trial in XLRP and Cariad Chester, Managing Partner at TGCX, has joined the Board of Directors. We look forward to working with our friends at Forbion and Syncona Limited to rapidly advance these transformative therapies. For more information on Beacon, please see the press release: https://lnkd.in/eZ9mrd6K

TCGX led the $120M Series B financing this week into Pheon Therapeutics, a London-based biopharma company that are developing three ADC assets for the targeting of hard-to-treat solid tumor cancer cells. Our Managing Partner, Cariad Chester, will join the Board of Directors at Pheon. To learn more about the deal, please read below: https://lnkd.in/edC3iPgX

Nasdaq also recognized Chen Yu yesterday after receiving his A-List Award on Tuesday night from the Ascend gala at The Plaza in New York. Congratulations, Chen. A well-deserved honor and fun seeing you recognized (digitally) on a Times Square landmark billboard!

a special congratulations to the awardees from Tuesday night's Gala at The Plaza in Manhattan to celebrate excellence & leadership in the Pan-Asian business community. This gala was hosted by Ascend which aims to promote and advance Asian & Pacific Islander (API) professionals globally. Dr. Chen Yu, Managing Partner and Founder of TCGX, was celebrated for his tremendous accomplishments and for the leadership & standard of excellence he has set as an Asian-American entrepreneur and biotech investor propelling innovation in life science & drug discovery. https://lnkd.in/gTicTsD7

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million https://lnkd.in/ePTuMRun

TCGX, a later-stage clinical phase biotechnology firm, is delighted to announce the closing of a $1B oversubscribed Fund II as of this morning. The TCGX team are delighted to continue our partnerships across both the private and public biotech company landscape as we continue to fuel the surge of innovation we are seeing across life sciences. We want to thank our limited partners for their support and the phenomenal CEOs we have worked with since we established TCG Crossover back in 2020.

We are happy to share news of another M&A outcome for TCGX and our active investment into life-changing therapeutics for weight-loss & obesity as part of our active metabolic theme. Earlier this week, Carmot Therapeutics entered into a definitive merger agreement with Roche: https://lnkd.in/gDRESJkU